Abstract Details
|
Suzete N. Farias Da Guarda, MD, PhD
(Massachusetts General Hospital)
PRESENTER |
Prof. Farias Da Guarda has nothing to disclose. |
| Maria Clara Zanon Zotin, MD, PhD | Dr. Zanon Zotin has nothing to disclose. |
| Hilde d. van den Brink, PhD | Ms. van den Brink has nothing to disclose. |
| Dorothee Schoemaker, PhD | Dr. Schoemaker has received personal compensation for serving as an employee of WCG. |
| Anthipa Chokesuwattanaskul, MD | Dr. Chokesuwattanaskul has nothing to disclose. |
| Steven M. Greenberg, MD, PhD, FAAN | Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squib. The institution of Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Greenberg has received research support from National Institutes of Health. Dr. Greenberg has received publishing royalties from a publication relating to health care. |
| Anand Viswanathan, MD (Massachusetts General Hospital) | Dr. Viswanathan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam Pharmaceuticals. Dr. Viswanathan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Viswanathan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Pharmaceuticals. |